CSTONE Aktie

>CSTONE Aktienkurs

0.62 EUR +6.9% (TradegateBSX)

Ask: 0.66 EUR / 3023 Stück

Bid: 0.62 EUR / 3228 Stück

Tagesumsatz: 500 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

CSTONE Aktie über LYNX handeln

Intraday

1 Jahr

>CSTONE Performance

1 Woche: +11,7%

1 Monat: -7,1%

3 Monate: +4,2%

6 Monate: -23,0%

1 Jahr: +110,9%

laufendes Jahr: +3,3%

>CSTONE Aktie

Name:

CSTONE PHARMAC. DL-,0001

Land:

China

Sektor:

Gesundheit

ISIN/ Wkn:

KYG2588M1006 / A2PEFW

Symbol/ Ticker:

PH4 (Frankfurt)

Kürzel:

FRA:PH4, ETR:PH4, PH4:GR

Index:

Webseite:

http://www.cstonepharma.c..

Profil:

CStone Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative oncology therapies. It primarily focuses on developing groundbreaking..
>Volltext..

Marktkapitalisierung:

927.09 Mio. EUR

Unternehmenswert:

896.13 Mio. EUR

Umsatz:

23.51 Mio. EUR

EBITDA:

-37.06 Mio. EUR

Nettogewinn:

-43.58 Mio. EUR

Gewinn je Aktie:

-0.03 EUR

Schulden:

46.01 Mio. EUR

Liquide Mittel:

53.81 Mio. EUR

Operativer Cashflow:

-50.71 Mio. EUR

Bargeldquote:

1.04

Umsatzwachstum:

-59.88%

Gewinnwachstum:

-139.04%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CSTONE

Letzte Datenerhebung:

15.02.26

>CSTONE Kennzahlen

Aktien/ Unternehmen:

Aktien: 1472.4 Mio. St.

Frei handelbar: 71.71%

Leerverk. Aktien: -

Rückkaufquote: -2.69%

Mitarbeiter: 135

Umsatz/Mitarb.: 0.35 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 168.2%

Bewertung:

KGV: -

KGV lG: -

KUV: 34.51

KBV: 21.15

PEG-Ratio: -0.12

EV/EBITDA: -

Rentabilität:

Bruttomarge: -34.62%

Gewinnmarge: -185.36%

Operative Marge: -181.2%

Managementeffizenz:

Gesamtkaprendite: -27.52%

Eigenkaprendite: -95.84%

>CSTONE Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>CSTONE Chart & Kurs - Tradegate

>CSTONE News

16.02.26 - 01:12	CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial (PR Newswire)
	CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial in patients with advanced solid tumors. This marks a significant milestone in the global development......

07.11.25 - 01:12	ACAAI 2025 \| CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut (PR Newswire)
	SUZHOU, China, Nov. 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced that the......

20.10.25 - 02:12	ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) (PR Newswire)
	SUZHOU, China, Oct. 19, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced the first......

09.07.25 - 03:45	CSTONE PHARMA-B Places 100M Shrs at ~9% Discount to Raise HKD472M (AAStocks)
	Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

07.05.25 - 02:03	CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR (PR Newswire)
	SUZHOU, China, May 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that poster presentations of preclinical data of CS2011 (EGFR/HER3 bispecific antibody), CS5007......

06.05.25 - 02:01	CStone Presents the Latest Preclinical Findings of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) at 2025 AACR (PR Newswire)
	SUZHOU, China, May 5, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that a poster presentation of preclinical data of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody), a......

27.03.25 - 12:57	CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress (PR Newswire)
	Financial Performance: Strong Year-over-Year Improvement - Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income. - Net Loss Reduction: 71.5% year-over-year improvement. Key Product Advancements - Sugemalimab (Anti-PD-L1 mAb) - Regulatory......

26.03.25 - 01:18	CStone to Showcase Five Latest Research Achievements at AACR 2025 (PR Newswire)
	SUZHOU, China, March 25, 2025 /PRNewswire/ -- From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place in Chicago. CStone will showcase its latest preclinical studies on five internally developed innovative candidates, including the......

24.03.25 - 01:15	CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer (PR Newswire)
	SUZHOU, China, March 23, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for......

06.03.25 - 01:12	CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL (PR Newswire)
	Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape. CS5001 is also being investigated globally in a multi-center Phase Ib clinical trial for multiple solid tumor......

04.03.25 - 01:12	CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody (PR Newswire)
	SUZHOU, China, March 3, 2025 /PRNewswire/ --CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient has been successfully dosed in the global......

25.02.25 - 05:12	CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA (PR Newswire)
	Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The GEMSTONE-303 study results support sugemalimab in combination with chemotherapy as a new standard first-line treatment for......

27.01.25 - 05:33	CStone Partners with SteinCares to Market Sugemalimab in Latin America (PR Newswire)
	CStone will receive upfront, regulatory and commercial milestone payments, and book revenue from SteinCares through the supply of sugemalimab in 10 Latin American (LATAM) countries. This marks CStone's third major global commercialization partnership for sugemalimab, with additional deals......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Auf Kontinuität setzen vor allem die, denen noch nie etwas Neues eingefallen ist. - Dr. Fritz P. Rinnhofer

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram